Cargando…

The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells

BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sennoune, Souad R., Nelius, Thomas, Jarvis, Courtney, Pruitt, Kevin, Kottapalli, Kameswara Rao, Filleur, Stéphanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266300/
https://www.ncbi.nlm.nih.gov/pubmed/32484838
http://dx.doi.org/10.1371/journal.pone.0234078
_version_ 1783541280845856768
author Sennoune, Souad R.
Nelius, Thomas
Jarvis, Courtney
Pruitt, Kevin
Kottapalli, Kameswara Rao
Filleur, Stéphanie
author_facet Sennoune, Souad R.
Nelius, Thomas
Jarvis, Courtney
Pruitt, Kevin
Kottapalli, Kameswara Rao
Filleur, Stéphanie
author_sort Sennoune, Souad R.
collection PubMed
description BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel’s mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel’s resistance mechanisms. METHODS: Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies. RESULTS: While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance. CONCLUSION: Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies.
format Online
Article
Text
id pubmed-7266300
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-72663002020-06-10 The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells Sennoune, Souad R. Nelius, Thomas Jarvis, Courtney Pruitt, Kevin Kottapalli, Kameswara Rao Filleur, Stéphanie PLoS One Research Article BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel’s mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel’s resistance mechanisms. METHODS: Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies. RESULTS: While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance. CONCLUSION: Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies. Public Library of Science 2020-06-02 /pmc/articles/PMC7266300/ /pubmed/32484838 http://dx.doi.org/10.1371/journal.pone.0234078 Text en © 2020 Sennoune et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sennoune, Souad R.
Nelius, Thomas
Jarvis, Courtney
Pruitt, Kevin
Kottapalli, Kameswara Rao
Filleur, Stéphanie
The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title_full The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title_fullStr The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title_full_unstemmed The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title_short The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
title_sort wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266300/
https://www.ncbi.nlm.nih.gov/pubmed/32484838
http://dx.doi.org/10.1371/journal.pone.0234078
work_keys_str_mv AT sennounesouadr thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT neliusthomas thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT jarviscourtney thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT pruittkevin thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT kottapallikameswararao thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT filleurstephanie thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT sennounesouadr wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT neliusthomas wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT jarviscourtney wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT pruittkevin wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT kottapallikameswararao wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells
AT filleurstephanie wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells